Biodel Inc. · Danbury, CT United States (NASDAQ: BIOD)
| 100 Saw Mill Rd. | Phone: 203-796-5000 |
| Danbury, CT | Fax: 203-796-5001 |
| 06810 | |
| United States | 
Map This Company |
Biodel Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Biodel delves into the development of viable treatments for diabetes. The company uses its VIAdel biological technology to reformulate and administer existing peptide hormones (such as insulin) for the treatment of diabetes and its complications including hyper- and hypoglycemia, cardiovascular problems, and weight control. Its two lead product candidates are VIAject, an injectable insulin formulation designed to be rapidly absorbed into the bloodstream, and VIAtab tablets which are administered sublingually (under the tongue). Both candidates are in clinical trials; VIAject is closest to commercialization. Biodel has three other diabetes-related candidates in its pipeline at varying stages of development.
Biodel Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: BIOD Headquarters |
|---|---|
| Fiscal Year-End | September |
| 2010 Employees | 55 |
Executives
23 executives listed for Biodel Inc.'s Danbury, CT location.
| Chairman | Charles Sanders | |
|---|---|---|
| President, CEO, and Director | Errol De Souza | |
| VP Operations | Erik Steiner |